

# **Gliosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update**

<https://marketpublishers.com/r/G18F0892C774EN.html>

Date: October 2022

Pages: 105

Price: US\$ 2,000.00 (Single User License)

ID: G18F0892C774EN

## **Abstracts**

Gliosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

### **SUMMARY**

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gliosarcoma - Drugs In Development, 2022, provides an overview of the Gliosarcoma (Oncology) pipeline landscape.

Gliosarcoma is a type of brain tumor that originates from glial cells. The tumor grows rapidly and symptom will vary depending on the exact location and size of the tumor. Most likely they may be headache, vomiting, cognitive problems, and drowsiness. Treatment of brain tumors depends upon the type and staging of the tumor, its size and position in the brain, as well as the age and other health problems of patient.

### **REPORT HIGHLIGHTS**

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gliosarcoma - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Gliosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gliosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gliosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 4, 13, 20 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0 and Preclinical stages comprises 1, 1, 2 and 1 molecules, respectively.

Gliosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Gliosarcoma (Oncology).

The pipeline guide reviews pipeline therapeutics for Gliosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Gliosarcoma (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Gliosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Gliosarcoma (Oncology)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Gliosarcoma (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Gliosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



## Contents

Introduction
Global Markets Direct Report Coverage
Gliosarcoma - Overview
Gliosarcoma - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Gliosarcoma - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Gliosarcoma - Companies Involved in Therapeutics Development
A. Menarini Industrie Farmaceutiche Riunite Srl
Aettis Inc
Apexigen Inc
Arog Pharmaceuticals Inc
Bayer AG
Berg LLC
Biohaven Pharmaceutical Holding Company Ltd
Bristol-Myers Squibb Co
Calithera Biosciences Inc
CDG Therapeutics Inc
Chimerix Inc
Cothara Bioscience Pty Ltd
DNATRIX Inc
EpicentRx Inc
ERC Belgium SA
F. Hoffmann-La Roche Ltd
Fore Biotherapeutics Inc
Genexine Inc
Ipsen SA
Kazia Therapeutics Ltd
Kintara Therapeutics Inc
Lentigen Technology Inc

Merck & Co Inc  
Merck KGaA  
Mustang Bio Inc  
Novartis AG  
OncXerna Therapeutics Inc  
Samus Therapeutics Inc  
TheraBiologics Inc  
Transtarget Inc  
Vascular Biogenics Ltd  
Vigeo Therapeutics Inc  
Gliosarcoma - Drug Profiles  
atezolizumab - Drug Profile  
Product Description  
Mechanism Of Action  
avadomide hydrochloride - Drug Profile  
Product Description  
Mechanism Of Action  
bavituximab - Drug Profile  
Product Description  
Mechanism Of Action  
CB-NK-TGF-betaR2 - Drug Profile  
Product Description  
Mechanism Of Action  
Cellular Immunotherapy for Oncology - Drug Profile  
Product Description  
Mechanism Of Action  
Cellular Immunotherapy for Oncology - Drug Profile  
Product Description  
Mechanism Of Action  
Cellular Immunotherapy to Target CD3 and EGFR for Oncology - Drug Profile  
Product Description  
Mechanism Of Action  
crenolanib besylate - Drug Profile  
Product Description  
Mechanism Of Action  
dianhydrogalactitol - Drug Profile  
Product Description  
Mechanism Of Action  
efineptakin alfa - Drug Profile

Product Description  
Mechanism Of Action  
ERC-1671 - Drug Profile  
Product Description  
Mechanism Of Action  
FORE-8394 - Drug Profile  
Product Description  
Mechanism Of Action  
G-207 - Drug Profile  
Product Description  
Mechanism Of Action  
icapamespib - Drug Profile  
Product Description  
Mechanism Of Action  
ipilimumab - Drug Profile  
Product Description  
Mechanism Of Action  
ipilimumab + nivolumab - Drug Profile  
Product Description  
Mechanism Of Action  
irinotecan hydrochloride - Drug Profile  
Product Description  
Mechanism Of Action  
LG-631 - Drug Profile  
Product Description  
Mechanism Of Action  
lonafarnib - Drug Profile  
Product Description  
Mechanism Of Action  
M-032 - Drug Profile  
Product Description  
Mechanism Of Action  
marizomib - Drug Profile  
Product Description  
Mechanism Of Action  
MB-108 - Drug Profile  
Product Description  
Mechanism Of Action  
NU-0129 - Drug Profile

Product Description  
Mechanism Of Action  
ofranergene obadenovec - Drug Profile  
Product Description  
Mechanism Of Action  
ONC-201 - Drug Profile  
Product Description  
Mechanism Of Action  
ONC-206 - Drug Profile  
Product Description  
Mechanism Of Action  
P-28 - Drug Profile  
Product Description  
Mechanism Of Action  
paxalisib - Drug Profile  
Product Description  
Mechanism Of Action  
pazopanib hydrochloride - Drug Profile  
Product Description  
Mechanism Of Action  
pembrolizumab - Drug Profile  
Product Description  
Mechanism Of Action  
relatlimab - Drug Profile  
Product Description  
Mechanism Of Action  
RRX-001 - Drug Profile  
Product Description  
Mechanism Of Action  
sabatolimab - Drug Profile  
Product Description  
Mechanism Of Action  
sapanisertib - Drug Profile  
Product Description  
Mechanism Of Action  
SL-701 - Drug Profile  
Product Description  
Mechanism Of Action  
sorafenib tosylate - Drug Profile



Product Description  
Mechanism Of Action  
sotigalimab - Drug Profile  
Product Description  
Mechanism Of Action  
tasadenoturev - Drug Profile  
Product Description  
Mechanism Of Action  
TBX.OncV NSC - Drug Profile  
Product Description  
Mechanism Of Action  
tepotinib hydrochloride - Drug Profile  
Product Description  
Mechanism Of Action  
troriluzole hydrochloride - Drug Profile  
Product Description  
Mechanism Of Action  
ubidecarenone - Drug Profile  
Product Description  
Mechanism Of Action  
urelumab - Drug Profile  
Product Description  
Mechanism Of Action  
vorinostat - Drug Profile  
Product Description  
Mechanism Of Action  
VT-1021 - Drug Profile  
Product Description  
Mechanism Of Action  
zotiraciclib citrate - Drug Profile  
Product Description  
Mechanism Of Action  
Gliosarcoma - Dormant Projects  
Gliosarcoma - Discontinued Products  
Appendix  
Methodology  
Coverage  
Secondary Research  
Primary Research

[Expert Panel Validation](#)

[Contact Us](#)

[Disclaimer](#)

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Gliosarcoma, 2022  
Number of Products under Development by Companies, 2022  
Number of Products under Development by Universities/Institutes, 2022  
Products under Development by Companies, 2022  
Products under Development by Universities/Institutes, 2022  
Number of Products by Stage and Target, 2022  
Number of Products by Stage and Mechanism of Action, 2022  
Number of Products by Stage and Route of Administration, 2022  
Number of Products by Stage and Molecule Type, 2022  
Gliosarcoma - Dormant Projects, 2022  
Gliosarcoma - Discontinued Products, 2022

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Gliosarcoma, 2022  
Number of Products under Development by Companies, 2022  
Number of Products under Development by Universities/Institutes, 2022  
Number of Products by Top 10 Targets, 2022  
Number of Products by Stage and Top 10 Targets, 2022  
Number of Products by Top 10 Mechanism of Actions, 2022  
Number of Products by Stage and Top 10 Mechanism of Actions, 2022  
Number of Products by Top 10 Routes of Administration, 2022  
Number of Products by Stage and Top 10 Routes of Administration, 2022  
Number of Products by Top 10 Molecule Types, 2022  
Number of Products by Stage and Top 10 Molecule Types, 2022

## I would like to order

Product name: Gliosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/G18F0892C774EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G18F0892C774EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

